TrialsgrambetaRCTs are beautiful
ESC Congress 2026Presentato sab 29 ago · 11:00 CESTHot Line 3Tutti gli studi Hot Line →

LIBREXIA ACS

2026

A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome (Librexia ACS)

In 14,194 patients with a recent acute coronary syndrome, milvexian added to antiplatelet therapy did not reduce cardiovascular death, myocardial infarction or ischaemic stroke compared with placebo.

Risultato

Efficacia: Time to first occurrence of the composite of cardiovascular death, myocardial infarction or ischaemic strokeHR 1,05 (IC 95% 0,91-1,21) · P = 0,50

Sicurezza: Intracranial or fatal bleedingHR 1,04 (IC 95% 0,58-1,87) · P = 0,88

Sotto 1 a favore di milvexian added to antiplatelet therapy, sopra 1 a favore di placebo.

Tassi di eventi Milvexian added to antiplatelet therapy 5,4% vs placebo 5,1% (time to first occurrence of the composite of cardiovascular death, myocardial infarction or ischaemic stroke)

Riportato inoltre: Cardiovascular death, myocardial infarction or ischaemic stroke . Stopped for futility at the interim analysis in November 2025.

Pubblicazione originale
Sottotema
Factor XIa inhibition
Disegno
International, multicentre, randomised, double-blind (quadruple-masked), placebo-controlled, event-driven phase 3 trial; 1:1 allocation to milvexian or matched placebo on top of investigator-chosen standard antiplatelet therapy (SAPT or DAPT); randomisation stratified by planned type and duration of antiplatelet therapy; follow-up planned until 875 primary-endpoint events (up to about 3.5 years)
Rilevanza
Importante: uno dei diversi pilastri.
Fonte
Gibson CM, Steg PG, Bahit MC, et al. N Engl J Med. 2026; published online 29 August.doi 10.1056/nejmoa2608717

Discussione e critica

Factor XI inhibition promised the separation every antithrombotic programme is chasing: fewer events without more bleeding. In 14,194 patients after an acute coronary syndrome, milvexian delivered the second half and none of the first: identical bleeding, identical events, stopped for futility. The bleeding safety is real and matters for the atrial fibrillation and stroke programmes still running, but on top of modern antiplatelet therapy after ACS there was nothing left to prevent.

Discusso nei podcast